Can Gilead Stock Outrun Regeneron In The Next Rally?

Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?
Medpage Today on MSN

Regulatory T-Cell Drug Promising for Eczema, With Hint for Asthma as Well

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...
Fierce Pharma

TV ad spending skyrocketed to new heights in October, led by record outlay for J&J's Tremfya

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...
pharmaphorum

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication after severe asthma. The anti-TSLP antibody has ...